Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PHGE 
Biomx Inc (PHGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PHGE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.86% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.78M USD | Price to earnings Ratio 0.02 | 1Y Target Price 15.5 |
Price to earnings Ratio 0.02 | 1Y Target Price 15.5 | ||
Volume (30-day avg) 2 | Beta 1.44 | 52 Weeks Range 0.34 - 3.86 | Updated Date 07/1/2025 |
52 Weeks Range 0.34 - 3.86 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 23.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.6% | Return on Equity (TTM) -34.02% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value 19600339 | Price to Sales(TTM) - |
Enterprise Value 19600339 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.25 | Shares Outstanding 26176300 | Shares Floating 16063355 |
Shares Outstanding 26176300 | Shares Floating 16063355 | ||
Percent Insiders 19.08 | Percent Institutions 47.7 |
Analyst Ratings
Rating 2 | Target Price 15.5 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biomx Inc
Company Overview
History and Background
BioMx Inc., founded in 2015, is a clinical-stage biotechnology company focused on developing therapies targeting the microbiome to treat chronic diseases. It is based in Ness Ziona, Israel. It has undergone multiple clinical trials, mainly focusing on inflammatory bowel disease and acne vulgaris.
Core Business Areas
- Phage Therapy: Developing engineered phage cocktails to target and kill specific harmful bacteria in the human microbiome.
- Therapeutic Programs: Clinical development programs targeting inflammatory bowel disease (IBD) and acne vulgaris.
Leadership and Structure
Eran Ofir is the CEO. The company has a board of directors and operates with a team of scientists and clinical development professionals. The company restructured in 2024 shifting focus.
Top Products and Market Share
Key Offerings
- BX001: A phage therapy product candidate targeting Klebsiella pneumoniae for the treatment of primary sclerosing cholangitis (PSC). Currently in clinical development. There are other competitors in this space exploring different methods of microbiome modulation, but not direct competitors as of late 2024.
- Acne Phage Therapy: Phage-based therapies for acne vulgaris, targeting Cutibacterium acnes. Currently in clinical development. Competitors include companies developing topical antibiotics and other acne treatments.
Market Dynamics
Industry Overview
The microbiome therapeutics industry is rapidly growing, with increasing interest in using the microbiome to treat a wide range of diseases. This includes phage therapy, fecal microbiota transplantation (FMT), and other microbiome modulation approaches.
Positioning
BioMx is positioned as a leader in developing phage therapy for microbiome modulation. It focuses on precision targeting of specific bacteria to treat diseases.
Total Addressable Market (TAM)
The TAM for microbiome therapeutics is projected to reach billions of dollars. BioMx is positioned to capture a portion of this market with its phage therapy platform. Specific estimates are difficult to pinpoint without detailed clinical trial success projections, but IBD and acne represent substantial markets.
Upturn SWOT Analysis
Strengths
- Proprietary phage therapy platform
- Expertise in microbiome modulation
- Clinical-stage product candidates
- Focus on precision targeting of bacteria
Weaknesses
- Limited financial resources
- High risk associated with clinical development
- Dependence on successful clinical trial outcomes
- Restructuring in 2024 created uncertainty
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new disease areas
- Advancements in phage engineering technology
- Increasing awareness of the microbiome's role in health
Threats
- Competition from other microbiome companies
- Regulatory hurdles for phage therapy
- Potential for phage resistance
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- SNY
- CRSP
Competitive Landscape
BioMx faces competition from larger pharmaceutical companies and other microbiome companies. Its advantage lies in its expertise in phage therapy. It is a very small company competing with giants. Its success hinges on its phage platform.
Growth Trajectory and Initiatives
Historical Growth: BioMx's growth has been limited due to its pre-revenue stage. The company has focused on advancing its clinical pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analyst estimates are highly speculative.
Recent Initiatives: The company restructured in 2024 to refocus on key programs and reduce costs. This included employee layoffs and a pipeline prioritization.
Summary
BioMx is a high-risk, high-reward clinical-stage company focused on phage therapy. Its strength lies in its proprietary platform and expertise. However, it faces significant financial challenges and competition. The recent restructuring highlights the need for successful clinical trial outcomes to secure future funding and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomx Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2019-03-13 | CEO & Director Mr. Jonathan Eitan Solomon MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.biomx.com |
Full time employees 52 | Website https://www.biomx.com | ||
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.